Despite the threat of COVID-19 paralyzing much of the country in 2020, government health care fraud enforcement continued even though the Department of Justice (DOJ) had the added burden of pursuing COVID-19 related fraud. While criminal enforcement actions involving opioids remained a top enforcement priority, the civil False Claims Act (FCA) is still one of the government’s most powerful enforcement tools. In our annual webinar, Mintz’s Health Care Enforcement Defense team reviewed the key policy developments, settlements, and court decisions from 2020 and assessed their likely impact in 2021 and beyond.
- Statistical analysis of trends in qui tam litigation in 2020
- Examination of DOJ’s health care fraud enforcement priorities in 2020, including opioids, genetic testing, telemedicine, risk adjustment, and elder abuse
- Review of COVID-19 related fraud in 2020 and the possible shift toward increased civil investigations in this area in 2021
- Overview of new federal agency guidance and actions in 2020
- Outlook on regulatory and enforcement activity in 2021 under the Biden administration and anticipated targets, including pharmacies, consulting firms, EHR vendors, laboratories, and Medicare Advantage plans
For a deeper dive into these topics please read the accompanying report: Mintz's Health Care Enforcement 2020 Year in Review & 2021 Outlook.